Technical Analysis for CELG - Celgene Corporation

Grade Last Price % Change Price Change
grade D 95.61 1.95% 1.83
CELG closed up 1.95 percent on Friday, February 23, 2018, on 55 percent of normal volume.
24 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical CELG trend table...

Date Alert Name Type % Chg
Feb 23 Wide Bands Range Expansion 0.00%
Feb 22 Wide Bands Range Expansion 1.95%
Feb 21 Wide Bands Range Expansion 1.83%
Feb 20 MACD Bullish Signal Line Cross Bullish 1.88%
Feb 20 Wide Bands Range Expansion 1.88%
Feb 16 1,2,3 Retracement Bearish Bearish Swing Setup 0.37%
Feb 16 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.37%
Feb 16 NR7 Range Contraction 0.37%
Feb 16 Inside Day Range Contraction 0.37%
Feb 16 Wide Bands Range Expansion 0.37%

Older signals for CELG ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Its commercial stage products include REVLIMID, a drug to treat multiple myeloma and transfusion-dependent anemia; VIDAZA, a nucleoside analog to treat intermediate-2 and myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML); ABRAXANE, a chemotherapy treatment option for metastatic breast cancer; and THALOMID for multiple myeloma and the cutaneous manifestations of erythema nodosum leprosum. The company's commercial stage products also comprise ISTODAX to treat cutaneous T-cell lymphoma; POMALYST for the multiple myeloma and myelofibrosis treatment; and FOCALIN, FOCALIN XR, and RITALIN LA products. Its pre clinical and clinical stage products consist of CC-11050, an anti-inflammatory compound; CC-220, an anti-inflammatory product; cellular therapies, such as PDA-001 and PDA-002; CC-486 that is in Phase III trials to treat MDS and AML, as well as in a Phase I trials for solid tumor indications; and sotatercept and ACE-536, which are in Phase II trials to treat anemia. The company's pre clinical and clinical stage products also include CC-223, a dual TORK inhibitor; CC-292, a BTK inhibitor; CC-115, a dual TORK/DNA PK inhibitor; CC-122, a pleiotropic pathway modulator; and EPZ-5676, a DOT1L inhibitor. It has strategic collaborations with bluebird bio, Inc.; FORMA Therapeutics Holdings; Concert Pharmaceuticals, Inc.; Array BioPharma, Inc.; and Acetylon Pharmaceuticals, Inc., as well as a strategic alliance with MorphoSys AG. The company was founded in 1980 and is headquartered in Summit, New Jersey.
Is CELG a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 147.17
52 Week Low 88.32
Average Volume 7,172,091
200-Day Moving Average 119.4845
50-Day Moving Average 101.9772
20-Day Moving Average 96.35
10-Day Moving Average 93.892
Average True Range 2.649
ADX 36.03
+DI 15.13
-DI 29.36
Chandelier Exit (Long, 3 ATRs ) 98.723
Chandelier Exit (Short, 3 ATRs ) 96.267
Upper Bollinger Band 104.4345
Lower Bollinger Band 88.2655
Percent B (%b) 0.45
BandWidth 16.781526
MACD Line -2.3247
MACD Signal Line -2.6332
MACD Histogram 0.3085
Fundamentals Value
Market Cap 74.8 Billion
Num Shares 782 Million
EPS 3.23
Price-to-Earnings (P/E) Ratio 29.60
Price-to-Sales 6.42
Price-to-Book 9.26
PEG Ratio 0.67
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 98.19
Resistance 3 (R3) 97.92 96.79 97.76
Resistance 2 (R2) 96.79 96.13 96.93 97.62
Resistance 1 (R1) 96.20 95.73 96.50 96.47 97.47
Pivot Point 95.07 95.07 95.22 95.21 95.07
Support 1 (S1) 94.48 94.41 94.78 94.75 93.75
Support 2 (S2) 93.35 94.01 93.49 93.60
Support 3 (S3) 92.76 93.35 93.46
Support 4 (S4) 93.03